Ghent University Academic Bibliography

Advanced

Altered serum glycomics in Alzheimer disease: a potential blood biomarker?

Cuiying Chen UGent, Sebastiaan Engelborghs, Sylviane Dewaele UGent, Nathalie Le Bastard, Jean-Jacques Martin, Valerie Vanhooren UGent, Claude Libert UGent and Peter Paul De Deyn (2010) REJUVENATION RESEARCH. 13(4). p.439-444
abstract
We investigated whether blood N-glycan changes can be used as a diagnostic biomarker for Alzheimer disease (AD). We used DNA sequencer-assisted, fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology to assay N-glycans in sera from 79 autopsy-confirmed dementia patients and 149 healthy controls. One N-glycan (NA2F) was substantially decreased in AD patients but not in controls. Use of NA2F for discriminating AD between dementia patients and healthy controls showed a diagnostic accuracy of 85.7% +/- 2.8% with 92% specificity and 70% sensitivity. The decrease in the level of NA2F in AD patients compared to non-AD patients was more pronounced in females (p < 0.0001) than in males (p < 0.014). Use of NA2F to differentiate female AD from female non-AD patients reached a diagnostic accuracy of 90.7% +/- 4.8 %. Pearson correlation analysis showed that in female dementia patients, serum NA2F levels were significantly correlated with the cerebrospinal fluid (CSF) beta-amyloid peptide of 42 amino acids (A beta(1-42)) and tau phosphorylated at threonine 181 (P-tau(181P)) levels, whereas in male dementia patients serum NA2F levels were significantly correlated only with CSF total tau protein (T-tau) level. Thus, we suggest that the serum N-glycan marker might be suitable for longitudinal and follow-up studies.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
TAU, CSF, PROTEIN, GLYCOSYLATION, DEMENTIAS, DIAGNOSIS, GLYCANS, BETA
journal title
REJUVENATION RESEARCH
Rejuv. Res.
volume
13
issue
4
pages
439 - 444
Web of Science type
Article
Web of Science id
000281256000007
JCR category
GERIATRICS & GERONTOLOGY
JCR impact factor
4.225 (2010)
JCR rank
7/42 (2010)
JCR quartile
1 (2010)
ISSN
1549-1684
DOI
10.1089/rej.2009.0992
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1040769
handle
http://hdl.handle.net/1854/LU-1040769
date created
2010-09-10 13:17:14
date last changed
2012-06-26 14:32:07
@article{1040769,
  abstract     = {We investigated whether blood N-glycan changes can be used as a diagnostic biomarker for Alzheimer disease (AD). We used DNA sequencer-assisted, fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology to assay N-glycans in sera from 79 autopsy-confirmed dementia patients and 149 healthy controls. One N-glycan (NA2F) was substantially decreased in AD patients but not in controls. Use of NA2F for discriminating AD between dementia patients and healthy controls showed a diagnostic accuracy of 85.7\% +/- 2.8\% with 92\% specificity and 70\% sensitivity. The decrease in the level of NA2F in AD patients compared to non-AD patients was more pronounced in females (p {\textlangle} 0.0001) than in males (p {\textlangle} 0.014). Use of NA2F to differentiate female AD from female non-AD patients reached a diagnostic accuracy of 90.7\% +/- 4.8 \%. Pearson correlation analysis showed that in female dementia patients, serum NA2F levels were significantly correlated with the cerebrospinal fluid (CSF) beta-amyloid peptide of 42 amino acids (A beta(1-42)) and tau phosphorylated at threonine 181 (P-tau(181P)) levels, whereas in male dementia patients serum NA2F levels were significantly correlated only with CSF total tau protein (T-tau) level. Thus, we suggest that the serum N-glycan marker might be suitable for longitudinal and follow-up studies.},
  author       = {Chen, Cuiying and Engelborghs, Sebastiaan and Dewaele, Sylviane and Le Bastard, Nathalie and Martin, Jean-Jacques and Vanhooren, Valerie and Libert, Claude and De Deyn, Peter Paul},
  issn         = {1549-1684},
  journal      = {REJUVENATION RESEARCH},
  keyword      = {TAU,CSF,PROTEIN,GLYCOSYLATION,DEMENTIAS,DIAGNOSIS,GLYCANS,BETA},
  language     = {eng},
  number       = {4},
  pages        = {439--444},
  title        = {Altered serum glycomics in Alzheimer disease: a potential blood biomarker?},
  url          = {http://dx.doi.org/10.1089/rej.2009.0992},
  volume       = {13},
  year         = {2010},
}

Chicago
Chen, Cuiying, Sebastiaan Engelborghs, Sylviane Dewaele, Nathalie Le Bastard, Jean-Jacques Martin, Valerie Vanhooren, Claude Libert, and Peter Paul De Deyn. 2010. “Altered Serum Glycomics in Alzheimer Disease: a Potential Blood Biomarker?” Rejuvenation Research 13 (4): 439–444.
APA
Chen, Cuiying, Engelborghs, S., Dewaele, S., Le Bastard, N., Martin, J.-J., Vanhooren, V., Libert, C., et al. (2010). Altered serum glycomics in Alzheimer disease: a potential blood biomarker? REJUVENATION RESEARCH, 13(4), 439–444.
Vancouver
1.
Chen C, Engelborghs S, Dewaele S, Le Bastard N, Martin J-J, Vanhooren V, et al. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? REJUVENATION RESEARCH. 2010;13(4):439–44.
MLA
Chen, Cuiying, Sebastiaan Engelborghs, Sylviane Dewaele, et al. “Altered Serum Glycomics in Alzheimer Disease: a Potential Blood Biomarker?” REJUVENATION RESEARCH 13.4 (2010): 439–444. Print.